TGFB1 and neoplasm: Tumor mutational burden (TMB), microsatellite instability (MSI), T cell-inflamed microenvironment, and TGFβ expression profile are candidate biomarkers for CRC, but their analyses are expensive, delayed, and not easily available (56, 57).